150 related articles for article (PubMed ID: 27740519)
1. Chemerin, retinol binding protein-4, cytokeratin-18 and transgelin-2 presence in sera of patients with non-alcoholic liver fatty disease.
Zwolak A; Szuster-Ciesielska A; Daniluk J; Semeniuk J; Kandefer-Szerszen M
Ann Hepatol; 2016 Nov-Dec 2016; 15(6):862-869. PubMed ID: 27740519
[TBL] [Abstract][Full Text] [Related]
2. Serum Chemerin in Obese Children and Adolescents Before and After L-Carnitine Therapy: Relation to Nonalcoholic Fatty Liver Disease and Other Features of Metabolic Syndrome.
Hamza RT; Elkabbany ZA; Shedid AM; Hamed AI; Ebrahim AO
Arch Med Res; 2016 Oct; 47(7):541-549. PubMed ID: 28262196
[TBL] [Abstract][Full Text] [Related]
3. Irisin in patients with nonalcoholic fatty liver disease.
Polyzos SA; Kountouras J; Anastasilakis AD; Geladari EV; Mantzoros CS
Metabolism; 2014 Feb; 63(2):207-17. PubMed ID: 24140091
[TBL] [Abstract][Full Text] [Related]
4. Chemerin as a novel non-invasive serum marker of intrahepatic lipid content in obese children.
Kłusek-Oksiuta M; Bialokoz-Kalinowska I; Tarasów E; Wojtkowska M; Werpachowska I; Lebensztejn DM
Ital J Pediatr; 2014 Nov; 40():84. PubMed ID: 25399407
[TBL] [Abstract][Full Text] [Related]
5. Serum cytokeratin-18 and its relation to liver fibrosis and steatosis diagnosed by FibroScan and controlled attenuation parameter in nonalcoholic fatty liver disease and hepatitis C virus patients.
Darweesh SK; AbdElAziz RA; Abd-ElFatah DS; AbdElazim NA; Fathi SA; Attia D; AbdAllah M
Eur J Gastroenterol Hepatol; 2019 May; 31(5):633-641. PubMed ID: 30839434
[TBL] [Abstract][Full Text] [Related]
6. Correlation between serum cytokeratin-18 and the progression or regression of non-alcoholic fatty liver disease.
Kawanaka M; Nishino K; Nakamura J; Urata N; Oka T; Goto D; Suehiro M; Kawamoto H; Yamada G
Ann Hepatol; 2015; 14(6):837-44. PubMed ID: 26436355
[TBL] [Abstract][Full Text] [Related]
7. Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease.
Cusi K; Chang Z; Harrison S; Lomonaco R; Bril F; Orsak B; Ortiz-Lopez C; Hecht J; Feldstein AE; Webb A; Louden C; Goros M; Tio F
J Hepatol; 2014 Jan; 60(1):167-74. PubMed ID: 23973932
[TBL] [Abstract][Full Text] [Related]
8. Serum cytokeratin-18 fragment levels as noninvasive marker of nonalcoholic steatohepatitis in the chilean population.
Arab JP; Hernández-Rocha C; Morales C; Vargas JI; Solís N; Pizarro M; Robles C; Sandoval D; Ponthus S; Benítez C; Barrera F; Soza A; Riquelme A; Arrese M
Gastroenterol Hepatol; 2017; 40(6):388-394. PubMed ID: 28359548
[TBL] [Abstract][Full Text] [Related]
9. Plasma Cytokeratin-18 Level As a Novel Biomarker for Liver Fibrosis in Children With Nonalcoholic Fatty Liver Disease.
Mandelia C; Collyer E; Mansoor S; Lopez R; Lappe S; Nobili V; Alkhouri N
J Pediatr Gastroenterol Nutr; 2016 Aug; 63(2):181-7. PubMed ID: 26835904
[TBL] [Abstract][Full Text] [Related]
10. Serum chemerin and vaspin in non-alcoholic fatty liver disease.
Kukla M; Zwirska-Korczala K; Hartleb M; Waluga M; Chwist A; Kajor M; Ciupinska-Kajor M; Berdowska A; Wozniak-Grygiel E; Buldak R
Scand J Gastroenterol; 2010; 45(2):235-42. PubMed ID: 20095887
[TBL] [Abstract][Full Text] [Related]
11. Vaspin, resistin, retinol-binding protein-4, interleukin-1α and interleukin-6 in patients with nonalcoholic fatty liver disease.
Polyzos SA; Kountouras J; Polymerou V; Papadimitriou KG; Zavos C; Katsinelos P
Ann Hepatol; 2016; 15(5):705-14. PubMed ID: 27493109
[TBL] [Abstract][Full Text] [Related]
12. Reduced expression of chemerin in visceral adipose tissue associates with hepatic steatosis in patients with obesity.
Bekaert M; Ouwens DM; Hörbelt T; Van de Velde F; Fahlbusch P; Herzfeld de Wiza D; Van Nieuwenhove Y; Calders P; Praet M; Hoorens A; Geerts A; Verhelst X; Kaufman JM; Lapauw B
Obesity (Silver Spring); 2016 Dec; 24(12):2544-2552. PubMed ID: 27768254
[TBL] [Abstract][Full Text] [Related]
13. Hepatic chemerin mRNA expression is reduced in human nonalcoholic steatohepatitis.
Pohl R; Haberl EM; Rein-Fischboeck L; Zimny S; Neumann M; Aslanidis C; Schacherer D; Krautbauer S; Eisinger K; Weiss TS; Buechler C
Eur J Clin Invest; 2017 Jan; 47(1):7-18. PubMed ID: 27797398
[TBL] [Abstract][Full Text] [Related]
14. Nonalcoholic fatty liver disease: biomarkers as diagnostic tools for liver damage assessment in adult patients from Argentina.
Valva P; Rios D; Casciato P; Gadano A; Galdame O; Mullen E; Bertot G; de Matteo E; Preciado MV
Eur J Gastroenterol Hepatol; 2018 Jun; 30(6):637-644. PubMed ID: 29384795
[TBL] [Abstract][Full Text] [Related]
15. Obesity and metabolic syndrome as risk factors for the development of non-alcoholic fatty liver disease as diagnosed by ultrasound.
Petrović G; Bjelaković G; Benedeto-Stojanov D; Nagorni A; Brzački V; Marković-Živković B
Vojnosanit Pregl; 2016 Oct; 73(10):910-20. PubMed ID: 29327896
[TBL] [Abstract][Full Text] [Related]
16. Circulating dipeptidyl peptidase-4 activity correlates with measures of hepatocyte apoptosis and fibrosis in non-alcoholic fatty liver disease in type 2 diabetes mellitus and obesity: A dual cohort cross-sectional study.
Williams KH; Vieira De Ribeiro AJ; Prakoso E; Veillard AS; Shackel NA; Brooks B; Bu Y; Cavanagh E; Raleigh J; McLennan SV; McCaughan GW; Keane FM; Zekry A; Gorrell MD; Twigg SM
J Diabetes; 2015 Nov; 7(6):809-19. PubMed ID: 25350950
[TBL] [Abstract][Full Text] [Related]
17. Serum Chemerin Concentrations Associate with Beta-Cell Function, but Not with Insulin Resistance in Individuals with Non-Alcoholic Fatty Liver Disease (NAFLD).
Hatziagelaki E; Herder C; Tsiavou A; Teichert T; Chounta A; Nowotny P; Pacini G; Dimitriadis G; Roden M
PLoS One; 2015; 10(5):e0124935. PubMed ID: 25933030
[TBL] [Abstract][Full Text] [Related]
18. Association Between Serum CK-18 Levels and the Degree of Liver Damage in Fructose-Induced Metabolic Syndrome.
Bratoeva K; Nikolova S; Merdzhanova A; Stoyanov GS; Dimitrova E; Kashlov J; Conev N; Radanova M
Metab Syndr Relat Disord; 2018 Sep; 16(7):350-357. PubMed ID: 29989845
[TBL] [Abstract][Full Text] [Related]
19. Serum immunoreactive collagen IV detected by monoclonal antibodies as a marker of severe fibrosis in patients with non-alcoholic fatty liver disease.
Aida Y; Abe H; Tomita Y; Nagano T; Seki N; Sugita T; Itagaki M; Ishiguro H; Sutoh S; Aizawa Y
J Gastrointestin Liver Dis; 2015 Mar; 24(1):61-8. PubMed ID: 25822435
[TBL] [Abstract][Full Text] [Related]
20. The macrophage activation marker sCD163 is associated with morphological disease stages in patients with non-alcoholic fatty liver disease.
Kazankov K; Barrera F; Møller HJ; Rosso C; Bugianesi E; David E; Younes R; Esmaili S; Eslam M; McLeod D; Bibby BM; Vilstrup H; George J; Grønbaek H
Liver Int; 2016 Oct; 36(10):1549-57. PubMed ID: 27102725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
